According to the Zhitong Finance App, Boan Biotech (06955.HK) announced that the phase III clinical trial of the company's PD-1 inhibitor BA1104 (navulizumab injection) in China has been completed and reached the main end point. The company will soon submit a marketing license application for this product to the China National Drug Administration (NMPA). BA1104 is the first Odivo® (Opdivo®) biosimilar in China to complete phase III clinical trials. According to the “Technical Guidelines for Biosimilar Similarity Evaluation and Indication Extraction”, it is proposed to apply for Odivo® approved indications in China.

Zhitongcaijing · 1d ago
According to the Zhitong Finance App, Boan Biotech (06955.HK) announced that the phase III clinical trial of the company's PD-1 inhibitor BA1104 (navulizumab injection) in China has been completed and reached the main end point. The company will soon submit a marketing license application for this product to the China National Drug Administration (NMPA). BA1104 is the first Odivo® (Opdivo®) biosimilar in China to complete phase III clinical trials. According to the “Technical Guidelines for Biosimilar Similarity Evaluation and Indication Extraction”, it is proposed to apply for Odivo® approved indications in China.